Two market reports issued on Sept. 30, 2026, forecast substantial growth in outsourced drug-development and manufacturing services through 2035. ResearchAndMarkets.com projects the global full-service contract research organization (CRO) market to reach $45.6 billion by 2035 from 2026, expanding at a 7.4% compound annual growth rate, with clinical services, large enterprises and Asia-Pacific leading growth. SNS Insider values the global healthcare contract development and manufacturing organization (CDMO) market at USD 312.70 billion in 2025 and forecasts USD 814.75 billion by 2035, a 10.05% CAGR, driven by outsourcing, biologics, cell and gene therapies, antibody-drug conjugates and mRNA products. CRO growth is being shaped by artificial intelligence, decentralized trials, advanced analytics, data security and integrated services, while CDMOs are adopting single-use and continuous manufacturing, artificial intelligence and digital twins. Asia-Pacific is the fastest-growing region in both reports, while North America led the CDMO market with approximately 42.10% share in 2025. Regulatory complexity, cybersecurity and privacy risks, limited capacity, high operating costs and remediation expenses remain key challenges.